$ALXN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ALEXION PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ALEXION PHARMACEUTICALS, INC.. Get notifications about new insider transactions in ALEXION PHARMACEUTICALS, INC. for free.
Page: < prev 1 ... 5 6 7 8 9 10 11 12 13 ... 22 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Oct 30 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 124.06 | 39,537 | 4,904,960 | 105,686 | 145.2 K to 105.7 K (-27.23 %) |
Oct 30 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Buy | M | 93.83 | 7,600 | 713,108 | 145,223 | 137.6 K to 145.2 K (+5.52 %) |
Oct 30 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Buy | M | 78.88 | 32,437 | 2,558,631 | 137,623 | 105.2 K to 137.6 K (+30.84 %) |
Sep 18 2013 | ALXN | ALEXION PHARMACEUT ... | MADRI JOSEPH A | Director | Option Exercise | M | 5.55 | 30,000 | 166,500 | 0 | |
Sep 18 2013 | ALXN | ALEXION PHARMACEUT ... | MADRI JOSEPH A | Director | Sell | S | 115.00 | 30,000 | 3,450,000 | 179,217 | 209.2 K to 179.2 K (-14.34 %) |
Sep 18 2013 | ALXN | ALEXION PHARMACEUT ... | MADRI JOSEPH A | Director | Buy | M | 5.55 | 30,000 | 166,500 | 209,217 | 179.2 K to 209.2 K (+16.74 %) |
Sep 26 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 112.54 | 304 | 34,212 | 105,186 | 105.5 K to 105.2 K (-0.29 %) |
Sep 18 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 115.00 | 3,500 | 402,500 | 1,026,293 | 1 M to 1 M (-0.34 %) |
Sep 17 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 114.37 | 1,000 | 114,370 | 105,490 | 106.5 K to 105.5 K (-0.94 %) |
Sep 06 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Gift | G | 0.00 | 28,124 | 0 | 1,029,793 | 1 M to 1 M (+2.81 %) |
Sep 06 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 110.07 | 1,850 | 203,630 | 1,001,669 | 1 M to 1 M (-0.18 %) |
Sep 03 2013 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | SVP, Chief HR Offic ... | Sell | S | 107.53 | 37 | 3,979 | 9,463 | 9.5 K to 9.5 K (-0.39 %) |
Sep 03 2013 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | SVP, Chief HR Offic ... | Sell | S | 107.58 | 1,200 | 129,096 | 9,500 | 10.7 K to 9.5 K (-11.21 %) |
Sep 03 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 111.06 | 2,100 | 233,226 | 1,003,519 | 1 M to 1 M (-0.21 %) |
Sep 03 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 110.15 | 28,558 | 3,145,664 | 1,005,619 | 1 M to 1 M (-2.76 %) |
Sep 03 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 109.92 | 500 | 54,960 | 1,034,177 | 1 M to 1 M (-0.05 %) |
Sep 03 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 109.93 | 1,992 | 218,981 | 1,034,677 | 1 M to 1 M (-0.19 %) |
Aug 16 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 104.97 | 29,924 | 3,141,122 | 1,036,669 | 1.1 M to 1 M (-2.81 %) |
Aug 16 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 105.58 | 24,624 | 2,599,802 | 1,066,593 | 1.1 M to 1.1 M (-2.26 %) |
Aug 16 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 106.36 | 56,278 | 5,985,728 | 1,091,217 | 1.1 M to 1.1 M (-4.90 %) |
Aug 16 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 107.12 | 29,174 | 3,125,119 | 1,147,495 | 1.2 M to 1.1 M (-2.48 %) |
Aug 07 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 116.87 | 2,919 | 341,144 | 1,176,669 | 1.2 M to 1.2 M (-0.25 %) |
Aug 07 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 116.87 | 852 | 99,573 | 106,490 | 107.3 K to 106.5 K (-0.79 %) |
Aug 07 2013 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 116.87 | 852 | 99,573 | 310,808 | 311.7 K to 310.8 K (-0.27 %) |
Aug 07 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Sell | S | 116.87 | 730 | 85,315 | 88,178 | 88.9 K to 88.2 K (-0.82 %) |
Aug 02 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Option Exercise | M | 42.66 | 6,250 | 266,625 | 37,500 | |
Aug 02 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Option Exercise | M | 22.90 | 7,875 | 180,338 | 15,751 | |
Aug 02 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 116.12 | 1,392 | 161,639 | 107,342 | 108.7 K to 107.3 K (-1.28 %) |
Aug 02 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 114.95 | 4,858 | 558,427 | 108,734 | 113.6 K to 108.7 K (-4.28 %) |
Aug 02 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 116.04 | 2,963 | 343,827 | 113,592 | 116.6 K to 113.6 K (-2.54 %) |
Aug 02 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 115.05 | 4,912 | 565,126 | 116,555 | 121.5 K to 116.6 K (-4.04 %) |
Aug 02 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Buy | M | 42.66 | 6,250 | 266,625 | 121,467 | 115.2 K to 121.5 K (+5.42 %) |
Aug 02 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Buy | M | 22.90 | 7,875 | 180,338 | 115,217 | 107.3 K to 115.2 K (+7.34 %) |
Aug 01 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 110.86 | 2,737 | 303,424 | 1,179,588 | 1.2 M to 1.2 M (-0.23 %) |
Aug 01 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 121.01 | 6,112 | 739,613 | 1,182,325 | 1.2 M to 1.2 M (-0.51 %) |
Aug 01 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 120.09 | 39,099 | 4,695,399 | 1,188,437 | 1.2 M to 1.2 M (-3.19 %) |
Aug 01 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 119.74 | 10,001 | 1,197,520 | 1,227,536 | 1.2 M to 1.2 M (-0.81 %) |
Aug 01 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 118.27 | 17,376 | 2,055,060 | 1,237,537 | 1.3 M to 1.2 M (-1.38 %) |
Aug 01 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 117.24 | 10,817 | 1,268,185 | 1,254,913 | 1.3 M to 1.3 M (-0.85 %) |
Aug 01 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 116.11 | 27,900 | 3,239,469 | 1,265,730 | 1.3 M to 1.3 M (-2.16 %) |
Aug 01 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 114.85 | 100 | 11,485 | 1,293,630 | 1.3 M to 1.3 M (-0.01 %) |
Aug 01 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 113.12 | 200 | 22,624 | 1,293,730 | 1.3 M to 1.3 M (-0.02 %) |
Aug 01 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 112.56 | 4,200 | 472,752 | 1,293,930 | 1.3 M to 1.3 M (-0.32 %) |
Aug 01 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 111.04 | 6,125 | 680,120 | 1,298,130 | 1.3 M to 1.3 M (-0.47 %) |
Aug 01 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 110.53 | 50,967 | 5,633,383 | 1,304,255 | 1.4 M to 1.3 M (-3.76 %) |
Aug 01 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 109.56 | 37,103 | 4,065,005 | 1,355,222 | 1.4 M to 1.4 M (-2.66 %) |
Aug 01 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Sell | S | 110.86 | 746 | 82,702 | 88,908 | 89.7 K to 88.9 K (-0.83 %) |
Aug 01 2013 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 110.86 | 995 | 110,306 | 311,660 | 312.7 K to 311.7 K (-0.32 %) |
Aug 01 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 110.86 | 1,120 | 124,163 | 107,342 | 108.5 K to 107.3 K (-1.03 %) |
Jul 16 2013 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Option Exercise | M | 17.65 | 12,504 | 220,696 | 101,832 | |
Jul 16 2013 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Option Exercise | M | 11.92 | 37,496 | 446,952 | 0 | |
Jul 16 2013 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 120.00 | 50,000 | 6,000,000 | 312,655 | 362.7 K to 312.7 K (-13.79 %) |
Jul 16 2013 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Buy | M | 17.65 | 12,504 | 220,696 | 362,655 | 350.2 K to 362.7 K (+3.57 %) |
Jul 16 2013 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Buy | M | 11.92 | 37,496 | 446,952 | 350,151 | 312.7 K to 350.2 K (+11.99 %) |
Jul 16 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Option Exercise | S | 22.90 | 11,124 | 254,740 | 0 | |
Jul 16 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Option Exercise | S | 17.98 | 6,876 | 123,630 | 0 | |
Jul 16 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 119.90 | 18,000 | 2,158,200 | 108,462 | 126.5 K to 108.5 K (-14.23 %) |
Jul 16 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Buy | M | 22.90 | 11,124 | 254,740 | 126,462 | 115.3 K to 126.5 K (+9.64 %) |
Jul 16 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Buy | M | 17.98 | 6,876 | 123,630 | 115,338 | 108.5 K to 115.3 K (+6.34 %) |
Jul 16 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Option Exercise | M | 17.65 | 50,000 | 882,500 | 14,336 | |
Jul 16 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Sell | S | 120.00 | 50,000 | 6,000,000 | 89,654 | 139.7 K to 89.7 K (-35.80 %) |
Jul 16 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Buy | M | 17.65 | 50,000 | 882,500 | 139,654 | 89.7 K to 139.7 K (+55.77 %) |
Jul 03 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Global Ops. Of ... | Option Exercise | M | 22.90 | 7,875 | 180,338 | 11,124 | |
Jul 03 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Global Ops. Of ... | Option Exercise | M | 42.66 | 36,250 | 1,546,425 | 0 | |
Jul 03 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Global Ops. Of ... | Sell | S | 97.46 | 40 | 3,898 | 108,462 | 108.5 K to 108.5 K (-0.04 %) |
Jul 03 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Global Ops. Of ... | Sell | S | 96.84 | 7,285 | 705,479 | 108,502 | 115.8 K to 108.5 K (-6.29 %) |
Jul 03 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Global Ops. Of ... | Sell | S | 95.16 | 11,625 | 1,106,235 | 115,787 | 127.4 K to 115.8 K (-9.12 %) |
Jul 03 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Global Ops. Of ... | Sell | S | 94.34 | 25,175 | 2,375,010 | 127,412 | 152.6 K to 127.4 K (-16.50 %) |
Jul 03 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Global Ops. Of ... | Buy | M | 22.90 | 7,875 | 180,338 | 152,587 | 144.7 K to 152.6 K (+5.44 %) |
Jul 03 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Global Ops. Of ... | Buy | M | 42.66 | 36,250 | 1,546,425 | 144,712 | 108.5 K to 144.7 K (+33.42 %) |
Jun 07 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Option Exercise | M | 17.65 | 5,664 | 99,970 | 0 | |
Jun 07 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Option Exercise | M | 11.92 | 5,692 | 67,849 | 0 | |
Jun 07 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Option Exercise | M | 10.29 | 3,128 | 32,187 | 0 | |
Jun 07 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Option Exercise | M | 8.16 | 524 | 4,276 | 0 | |
Jun 07 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Buy | M | 17.65 | 5,664 | 99,970 | 89,654 | 84 K to 89.7 K (+6.74 %) |
Jun 07 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Buy | M | 11.92 | 5,692 | 67,849 | 83,990 | 78.3 K to 84 K (+7.27 %) |
Jun 07 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Buy | M | 10.29 | 3,128 | 32,187 | 78,298 | 75.2 K to 78.3 K (+4.16 %) |
Jun 07 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Buy | M | 8.16 | 524 | 4,276 | 75,170 | 74.6 K to 75.2 K (+0.70 %) |
May 23 2013 | ALXN | ALEXION PHARMACEUT ... | NORBY R DOUGLAS | Director | Option Exercise | M | 18.01 | 17,000 | 306,170 | 13,000 | |
May 23 2013 | ALXN | ALEXION PHARMACEUT ... | NORBY R DOUGLAS | Director | Option Exercise | M | 10.84 | 23,000 | 249,320 | 0 | |
May 23 2013 | ALXN | ALEXION PHARMACEUT ... | NORBY R DOUGLAS | Director | Sell | S | 100.11 | 11,186 | 1,119,830 | 56,144 | 67.3 K to 56.1 K (-16.61 %) |
May 23 2013 | ALXN | ALEXION PHARMACEUT ... | NORBY R DOUGLAS | Director | Sell | S | 102.59 | 4,610 | 472,940 | 67,330 | 71.9 K to 67.3 K (-6.41 %) |
May 23 2013 | ALXN | ALEXION PHARMACEUT ... | NORBY R DOUGLAS | Director | Sell | S | 104.03 | 24,204 | 2,517,942 | 71,940 | 96.1 K to 71.9 K (-25.17 %) |
May 23 2013 | ALXN | ALEXION PHARMACEUT ... | NORBY R DOUGLAS | Director | Buy | M | 18.01 | 17,000 | 306,170 | 96,144 | 79.1 K to 96.1 K (+21.48 %) |
May 23 2013 | ALXN | ALEXION PHARMACEUT ... | NORBY R DOUGLAS | Director | Buy | M | 10.84 | 23,000 | 249,320 | 79,144 | 56.1 K to 79.1 K (+40.97 %) |
May 22 2013 | ALXN | ALEXION PHARMACEUT ... | KELLER WILLIAM R | Director | Option Exercise | M | 85.75 | 3,237 | 277,573 | 0 | |
May 22 2013 | ALXN | ALEXION PHARMACEUT ... | KELLER WILLIAM R | Director | Option Exercise | M | 49.43 | 2,786 | 137,712 | 0 | |
May 22 2013 | ALXN | ALEXION PHARMACEUT ... | KELLER WILLIAM R | Director | Option Exercise | M | 23.05 | 3,747 | 86,368 | 0 | |
May 22 2013 | ALXN | ALEXION PHARMACEUT ... | KELLER WILLIAM R | Director | Sell | S | 103.00 | 9,770 | 1,006,310 | 12,276 | 22 K to 12.3 K (-44.32 %) |
May 22 2013 | ALXN | ALEXION PHARMACEUT ... | KELLER WILLIAM R | Director | Buy | M | 85.75 | 3,237 | 277,573 | 22,046 | 18.8 K to 22 K (+17.21 %) |
May 22 2013 | ALXN | ALEXION PHARMACEUT ... | KELLER WILLIAM R | Director | Buy | M | 49.43 | 2,786 | 137,712 | 18,809 | 16 K to 18.8 K (+17.39 %) |
May 22 2013 | ALXN | ALEXION PHARMACEUT ... | KELLER WILLIAM R | Director | Buy | M | 23.05 | 3,747 | 86,368 | 16,023 | 12.3 K to 16 K (+30.52 %) |
May 15 2013 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Option Exercise | A | 104.86 | 100,000 | 10,486,000 | 100,000 | |
May 15 2013 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Grant | A | 0.00 | 25,000 | 0 | 25,000 | 0 to 25 K |
May 15 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 107.48 | 2,333 | 250,751 | 1,361,212 | 1.4 M to 1.4 M (-0.17 %) |
May 15 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 106.32 | 6,566 | 698,097 | 1,363,545 | 1.4 M to 1.4 M (-0.48 %) |
May 15 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 105.38 | 22,214 | 2,340,911 | 1,370,111 | 1.4 M to 1.4 M (-1.60 %) |
May 14 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 104.94 | 6,220 | 652,727 | 1,392,325 | 1.4 M to 1.4 M (-0.44 %) |
May 14 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 100.12 | 35,000 | 3,504,200 | 1,398,545 | 1.4 M to 1.4 M (-2.44 %) |
May 09 2013 | ALXN | ALEXION PHARMACEUT ... | Veneman Ann M | Director | Option Exercise | A | 96.35 | 3,425 | 329,999 | 3,425 | |
May 09 2013 | ALXN | ALEXION PHARMACEUT ... | Rummelt Andreas | Director | Option Exercise | A | 96.35 | 3,425 | 329,999 | 3,425 | |
May 09 2013 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Option Exercise | A | 96.35 | 3,425 | 329,999 | 3,425 | |
May 09 2013 | ALXN | ALEXION PHARMACEUT ... | NORBY R DOUGLAS | Director | Option Exercise | A | 96.35 | 3,425 | 329,999 | 3,425 | |
May 09 2013 | ALXN | ALEXION PHARMACEUT ... | MADRI JOSEPH A | Director | Option Exercise | A | 96.35 | 3,425 | 329,999 | 3,425 | |
May 09 2013 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Option Exercise | A | 96.35 | 3,425 | 329,999 | 3,425 | |
May 09 2013 | ALXN | ALEXION PHARMACEUT ... | KELLER WILLIAM R | Director | Option Exercise | A | 96.35 | 3,425 | 329,999 | 3,425 | |
May 01 2013 | ALXN | ALEXION PHARMACEUT ... | Veneman Ann M | Director | Sell | S | 99.00 | 3,115 | 308,385 | 5,918 | 9 K to 5.9 K (-34.48 %) |
May 09 2013 | ALXN | ALEXION PHARMACEUT ... | LINK MAX | Director | Option Exercise | A | 96.35 | 3,425 | 329,999 | 3,425 | |
May 01 2013 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Sell | S | 99.03 | 3,115 | 308,478 | 29,456 | 32.6 K to 29.5 K (-9.56 %) |
May 01 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Global Ops. Of ... | Option Exercise | M | 42.66 | 20,000 | 853,200 | 30,000 | |
May 01 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Global Ops. Of ... | Option Exercise | M | 22.90 | 16,499 | 377,827 | 18,999 | |
May 01 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Global Ops. Of ... | Sell | S | 99.51 | 200 | 19,902 | 108,462 | 108.7 K to 108.5 K (-0.18 %) |
May 01 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Global Ops. Of ... | Sell | S | 98.96 | 36,299 | 3,592,149 | 108,662 | 145 K to 108.7 K (-25.04 %) |
May 01 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Global Ops. Of ... | Buy | M | 42.66 | 20,000 | 853,200 | 144,961 | 125 K to 145 K (+16.00 %) |
May 01 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Global Ops. Of ... | Buy | M | 22.90 | 16,499 | 377,827 | 124,961 | 108.5 K to 125 K (+15.21 %) |
Apr 26 2013 | ALXN | ALEXION PHARMACEUT ... | Islam Saqib | SVP, Chief Strat & ... | Option Exercise | M | 89.23 | 75,000 | 6,692,250 | 75,000 | |
Apr 26 2013 | ALXN | ALEXION PHARMACEUT ... | Islam Saqib | SVP, Chief Strat & ... | Buy | M | 0.00 | 25,000 | 0 | 25,000 | 0 to 25 K |
Apr 19 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 95.04 | 35,000 | 3,326,400 | 1,433,545 | 1.5 M to 1.4 M (-2.38 %) |
Apr 12 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 100.24 | 26,700 | 2,676,408 | 1,468,545 | 1.5 M to 1.5 M (-1.79 %) |
Apr 03 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 99.97 | 8,300 | 829,751 | 1,495,245 | 1.5 M to 1.5 M (-0.55 %) |
Apr 03 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 95.00 | 35,000 | 3,325,000 | 1,503,545 | 1.5 M to 1.5 M (-2.27 %) |
Mar 12 2013 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Sell | S | 92.00 | 3,115 | 286,580 | 7,311 | 10.4 K to 7.3 K (-29.88 %) |
Mar 12 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Head of R&D | Option Exercise | M | 22.90 | 6,250 | 143,125 | 59,124 | |
Mar 12 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Head of R&D | Option Exercise | M | 17.98 | 13,750 | 247,225 | 6,876 | |
Mar 12 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Head of R&D | Sell | S | 92.17 | 3,085 | 284,344 | 108,462 | 111.5 K to 108.5 K (-2.77 %) |
Mar 12 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Head of R&D | Sell | S | 91.21 | 16,915 | 1,542,817 | 111,547 | 128.5 K to 111.5 K (-13.17 %) |
Mar 12 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Head of R&D | Buy | M | 22.90 | 6,250 | 143,125 | 128,462 | 122.2 K to 128.5 K (+5.11 %) |
Mar 12 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Head of R&D | Buy | M | 17.98 | 13,750 | 247,225 | 122,212 | 108.5 K to 122.2 K (+12.68 %) |
Feb 08 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | A | 93.83 | 220,000 | 20,642,600 | 220,000 | |
Feb 08 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Grant | A | 0.00 | 16,500 | 0 | 1,538,545 | 1.5 M to 1.5 M (+1.08 %) |
Feb 08 2013 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | SVP, Chief HR Offic ... | Option Exercise | A | 93.83 | 35,600 | 3,340,348 | 35,600 | |
Feb 08 2013 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | SVP, Chief HR Offic ... | Grant | A | 0.00 | 2,700 | 0 | 10,700 | 8 K to 10.7 K (+33.75 %) |
Feb 08 2013 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | SVP & General Couns ... | Option Exercise | A | 93.83 | 29,600 | 2,777,368 | 29,600 | |
Feb 08 2013 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | SVP & General Couns ... | Grant | A | 0.00 | 2,200 | 0 | 17,200 | 15 K to 17.2 K (+14.67 %) |
Feb 08 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Head of R&D | Option Exercise | A | 93.83 | 60,800 | 5,704,864 | 60,800 | |
Feb 08 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Head of R&D | Grant | A | 0.00 | 4,500 | 0 | 108,462 | 104 K to 108.5 K (+4.33 %) |
Feb 08 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Option Exercise | A | 93.83 | 73,000 | 6,849,590 | 73,000 | |
Feb 08 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Grant | A | 0.00 | 5,400 | 0 | 74,646 | 69.2 K to 74.6 K (+7.80 %) |
Feb 08 2013 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Option Exercise | A | 93.83 | 60,800 | 5,704,864 | 60,800 | |
Feb 08 2013 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Grant | A | 0.00 | 4,500 | 0 | 312,655 | 308.2 K to 312.7 K (+1.46 %) |
Feb 08 2013 | ALXN | ALEXION PHARMACEUT ... | Wright Frank J | SVP, President Alxn ... | Option Exercise | A | 93.83 | 29,600 | 2,777,368 | 29,600 | |
Feb 08 2013 | ALXN | ALEXION PHARMACEUT ... | Wright Frank J | SVP, President Alxn ... | Grant | A | 0.00 | 2,200 | 0 | 14,700 | 12.5 K to 14.7 K (+17.60 %) |
Feb 08 2013 | ALXN | ALEXION PHARMACEUT ... | Veneman Ann M | Director | Grant | A | 0.00 | 2,471 | 0 | 9,033 | 6.6 K to 9 K (+37.66 %) |
Feb 08 2013 | ALXN | ALEXION PHARMACEUT ... | Rummelt Andreas | Director | Grant | A | 0.00 | 2,471 | 0 | 12,786 | 10.3 K to 12.8 K (+23.96 %) |
Feb 08 2013 | ALXN | ALEXION PHARMACEUT ... | NORBY R DOUGLAS | Director | Grant | A | 0.00 | 2,471 | 0 | 56,144 | 53.7 K to 56.1 K (+4.60 %) |
Feb 08 2013 | ALXN | ALEXION PHARMACEUT ... | KELLER WILLIAM R | Director | Grant | A | 0.00 | 2,471 | 0 | 12,276 | 9.8 K to 12.3 K (+25.20 %) |
Feb 08 2013 | ALXN | ALEXION PHARMACEUT ... | MADRI JOSEPH A | Director | Grant | A | 0.00 | 2,471 | 0 | 279,217 | 276.7 K to 279.2 K (+0.89 %) |
Feb 08 2013 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Grant | A | 0.00 | 2,471 | 0 | 32,571 | 30.1 K to 32.6 K (+8.21 %) |
Feb 08 2013 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Grant | A | 0.00 | 2,471 | 0 | 11,195 | 8.7 K to 11.2 K (+28.32 %) |
Feb 06 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 96.22 | 180 | 17,320 | 1,522,045 | 1.5 M to 1.5 M (-0.01 %) |